Skip over global navigation links
U.S. Department of Health and Human Services

CARB-X Partners

Antimicrobial resistance presents one of the greatest modern threats to public health.  We need innovative, global, solutions to address it. Each of the partners has a unique role to play in bringing new antibiotics through the development pipeline.

CARB-X is possibly the largest public-private partnership in the world dedicated to preclinical antibiotic development. It involves seven partners in the United States and the United Kingdom, and it is backed with half a billion dollars in funding. CARB-X partners are working together to set up a diverse portfolio with more than 20 high-quality antibacterial products. 

  • Biomedical Advanced Research and Development Authority (BARDA):  BARDA will draw on its extensive experience of successfully advancing promising medical countermeasures through late-stage development and provide $30 million during the project’s first year and up to $250 million during the five-year program.
  • National Institute of Allergy and Infectious Diseases (NIAID): NAID will provide in-kind services, including preclinical services, to projects that CARB-X supports. NIAID will also provide technical support related to early-stage antibiotic drug discovery and product development.
  • Wellcome Trust: Wellcome Trust will provide guidance for product developers covering a range of skillsets, including medicinal chemistry, biology, pharmaceutic formulation and clinical development. The Wellcome Trust will help monitor project progress and provide feedback and guidance through each milestone. It also provides business development support.
  • The AMR Centre:  The AMR Centre will provide funding, capacity and capability to support programs for CARB-X product developers, and pre-clinical expertise in chemistry, analytical, microbiology, drug metabolism and pharmacokinetics, and pharmacology. Together, Wellcome Trust and the AMR Centre will commit approximately $70 million in funding the first year and up to $250 million over the five-year program.
  • MassBio: MassBio will offer selectees access to capital and mentoring. This includes evaluating and providing feedback on commercial feasibility; identifying strengths, weaknesses, opportunities and threats; and teaming up to furnish industry-specific business advice for innovative ideas in therapeutics, diagnostics, medical devices and health information technology.
  • CLSI: CLSI will partner with MassBio to provide business support and mentoring services to developers selected for funding.  CLSI also will work to share best practices with the Wellcome Trust and AMR Centre, expanding the scope of business support services globally.
  • RTI International (RTI):  RTI will provide research support services to product developers in the partner accelerators.  RTI has also committed to build and run the computing systems to identify, track and monitor all research programs, including a real-time dashboard management information system.  It also will evaluate all CARB-X operations, share best practices across all partners, and support continuous quality improvement.
  • The Broad Institute of MIT and Harvard:  The Broad Institute will create an inter-disciplinary Collaborative Hub for Early Antibiotic Discovery (CHEAD) with a goal of advancing at least three products through shared chemistry services. CHEAD will be led by Dr. Deborah Hung, a Core Institute Member at the Broad and a co-director of its infectious disease program.
  • Boston University School of Law:  CARB-X will be hosted by the Boston University law school.  The CARB-X executive team will include Kevin Outterson, a leading health law researcher and collaborator in global projects to address antibiotic resistance, and experts with decades of experience in drug development, including in the area of antibacterial drugs.

Watch, Listen & Learn

YouTube:  Powered By CARB-X 
YouTube:  CARB-X Overview 

More Videos >>

  • This page last reviewed: March 30, 2017